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The involvement of miR-491-5p in breast cancer development is unclear. This study showed that
miR-491-5p is signiﬁcantly downregulated in ERa-positive breast cancer tissues and cell lines and
is generally hypermethylated in ERa-positive breast cancer. MiR-491-5p overexpression signiﬁcantly
suppressed estrogen signaling and estrogen-stimulated proliferation of breast cancer cells. Further-
more, the histone demethylase JMJD2B was identiﬁed as a direct target of miR-491-5p. The ectopic
expression of JMJD2B abrogated the phenotypic changes induced by miR-491-5p in breast cancer
cells. Collectively, our data indicate that miR-491-5p plays a tumor suppressor role in the develop-
ment and progression of breast caner and may be a novel therapeutic target against ERa-positive
breast cancer.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Breast cancer is the leading cause of cancer-related death in
women worldwide. Although it is a malignant tumor with high
level of heterogeneity, about 75% of breast cancers overexpress
estrogen receptor a (ERa) [1] which associates with numerous
cofactors to coordinately promote breast cancer growth and sur-
vival, and consequently, ERa-positive breast cancer patients can
be treated by hormonal therapy such as tamoxifen [2]. However,
a signiﬁcant portion of patients eventually fail to respond to hor-
monal therapy and develop resistance [3]. The molecular mechan-
isms of acquired resistance to hormonal therapy have not been
fully elucidated. Therefore, it is critical to further understand the
molecular mechanisms underlying deregulation of ERa signaling
to develop new strategies to improve the efﬁcacy of hormonal
therapy.
Lysine methylation in histones is an important epigenetic
modiﬁcation in the regulation of chromatin structure and gene
expression. This is a dynamic process that is controlled by histonemethyltransferases and demethylases [4]. Abnormalities in the
balance in methylation status of histones because of dysregulated
histone methyltransferases and demethylases have been linked to
cancer [5]. At present, two families of lysine demethylases have
been unveiled, one of which is referred to as the JmjC-domain-con-
taining proteins (JMJD) [6]. Recent studies have indicated that JMJD
proteins play important roles in tumorigenesis [7]. Members of the
JMJD2 subfamily that demethylate H3K9me3/me2 and H3K36me3/
me2 are overexpressed in various cancers. JMJD2B, a member of
the JMJD2 subfamily, is highly expressed in ERa-positive breast
cancer and prostate cancer [8,9]. It acts as a cofactor of estrogen
receptor a and facilitates transcription of ERa target genes, and
knockdown of JMJD2B severely impairs estrogen-induced cell pro-
liferation and the tumor formation capacity of breast cancer cells
[10]. These studies indicated that JMJD2B is necessary for the full
extent of ERa transcriptional activity. Despite its well-documented
role in hormonally responsive breast carcinogenesis, very little is
known about the regulation of JMJD2B. With respect to transcrip-
tional regulation, recent studies have shown that JMJD2B is a direct
target of HIF1a and positively regulated by HIF1a and ERa in
breast cancer [11]. In particular, very little is known about the post
transcriptional regulation of JMJD2B.
Table 1
Clinicopathologic characteristics of breast cancer patients.
Clinicopathologic parameters ERa-positive ERa-negative
Age (year)
<45 11 9
P45 15 14
Tumor size (cm)
<2 12 10
P2 14 13
TNM stage
I + II 10 11
III + IV 16 12
Lymph node metastasis
No 18 16
Yes 8 7
Her2 status
Negative 14 8
Positive 12 15
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ing RNAs (20–25 nucleotides in length) which regulate gene
expression and crucial biological processes via pairing of miRNAs
with the 30UTR of cognate mRNA targets, causing repression of
translation or mRNA decay [12]. It has been ﬁrmly established that
deregulation of miRNAs is a hallmark of cancer and that miRNAs
can function as tumor suppressors and oncogenes [13]. Altered
miRNAs expression has also been found in breast cancer [14,15].
It is particularly interesting that the status of ERa correlates with
the differential expression of several miRNAs, such as miR-206
[16], miR-22 [17] and miR-18a/b [18] which are down-regulated
in ERa-positive breast cancer and repress ERa expression by tar-
geting the ERa 30UTR. However, little is known about whether
there is a mechanistic link between the deregulation of miRNAs
expression and estrogen signaling through the cofactors of estro-
gen receptor. A recent microRNA microarray analysis showed that
miR-491-5p expression was signiﬁcantly decreased in ERa-posi-
tive breast cancers compared with ERa-negative ones [19], and a
large body of studies has found that miR-491-5p regulates tumor
progression in a variety of cancers as a tumor suppressor
[20–23]. In the present study, we identiﬁed the important molecu-
lar mechanism by which miR-491-5p exerts its negative effects on
breast cancer cell growth via direct targeting the 30UTR of JMJD2B
mRNA and affecting the ERa signaling pathway. In addition, the
molecular basis of miR-491-5p downregulated in ERa-positive
breast cancers was also analyzed.
2. Materials and methods
2.1. Clinical samples and cell lines
The primary breast cancer and corresponding normal adjacent
tissues were collected at the time of surgical resection from 2012
and 2013 in Wuhan Tumor Hospital, China. The samples were
immediately frozen in liquid nitrogen and stored at 80 C until
used. None of these patients received preoperative treatment, such
as radiation therapy or chemotherapy. Clinicopathologic informa-
tion about the patient samples used in this study is summarized
in Table 1. Specimens were obtained with informed consent and
the study was approved by local institutional review boards on
human subject research and in accordance with the Declaration
of Helsinki. All the histological diagnoses for breast cancer and nor-
mal tissues were reviewed and recognized by two pathologists
independently.
MDA-MB-436, MDA-MB-231, MDA-MB-468, BT549, MCF-7,
T47D, ZR-75-1 and BT483 cells were obtained from Chinese Center
for Type Culture Collection (Wuhan, China) and cultured in the rec-
ommended conditions. All cells were maintained in a humidiﬁed
incubator at 37 C and 5%CO2. For 17b-estradiol (E2) stimulation
experiments, cells were maintained for 3 days in phenol red-free
RPMI 1640 with 5% dextran-coated charcoal-treated serum before
E2 (10 nmol, Sigma–Aldrich) treatment.
2.2. RNA extraction and qRT-PCR
Total RNA was extracted using the RNeasy Mini kit (Qiagen)
according to the manufacturer’s instructions. For detection of
miR-491-5p expression, stem–loop RT-PCR was performed as
described [24]. Expression of U6 was used as an endogenous con-
trol. Real-time PCR was performed using FastStart Universal SYBR
Green Master kit (Roche Diagnostics) and analyzed with an Applied
Biosystems 7900 Real-Time PCR System. Primer sequences were as
follows: ERa, 50-GCTCTTGGACAGGAACCAGG-30 and 50-AAGATCTC-
CACCATGCCCTCT-30; JMJD2B, 50-GGGGAGGAAGATGTGAGTGA-30
and 50-GACGGCTTTTGGAGGGTAAT-30; TLE3, 50-TGGAGGTCCTGCACCACACTAA-30 and 50-GCTCACAAACCACTTGCCACA-30; TFF1, 50-GTG
TCACGCCCTCCCAGT-30 and 50-GGACCCCACGAACGGTG-30; GREB1,
50-CAGACCACCACAACCACACTCT-30 and 50-GGATGCCTTCCTTCTTCA
TAGTCA-30; GAPDH, 50-TGAACGGGAAGCTCACTGG-30 and 50-TCCAC
CACCCTGTTGCTGT-30. Fold changes in expression were calculated.
The data was analyzed using the method of 2DDCt relative
expression quantity as previously described [25]. All the qRT-PCR
reactions were run in triplicate and were repeated three times.
2.3. Cell proliferation, clonogenicity assay, cell-cycle and apoptosis
assays
The breast cancer cells (5  103 per well) were plated in 96-well
plates and transfected on the following day with 50nM miR-491-
5p-mimics, JMJD2B expression plasmid and their respective con-
trol using Lipofectamine 2000 (Invitrogen). Cell proliferation was
determined at 24, 48, 72 and 96 h using the CellTiter 96 AQueou-
sOne Solution Cell Proliferation Assay Kit (Promega), according to
the manufacturer’s instructions. For direct cell count, cells
(1  105 per well) were incubated in a 6-well plate. At the desired
time points, cells were trypsinized and counted using a hemocy-
tometer. For clonogenicity assay, cells were counted, seeded at
low density (1000 cells/plate) and allowed to grow until visible
colonies appeared. Then cells were stained with Giemsa and colo-
nies were counted. For the cell cycle analysis, cells were harvested
by trypsinization, washed twice using cold PBS and ﬁxed in 70%
ethanol overnight at 20 C. Then cells were treated with DNA
staining solution containing 3.4 mM Tris–Cl (pH 7.4), propodium
iodide, 0.1% triton X-100 buffer and 100 mg/ml RNase A. Cell cycle
analysis was performed with FACS ﬂow cytometry. For apoptosis
assay, cells were harvested by trypsinization, washed twice by
PBS and processed with the Annexin V FITC/PI apoptosis detection
kit (BD Biosciences) according to the manufacturer’s instructions.
The assays were performed in triplicate and were repeated three
times.
2.4. Western blot analysis
Breast cancer cells were harvested after 48 h treatment with
50 nM miR-491-5p mimics and corresponding controls. Protein
extraction, SDS–PAGE gel electrophoresis and blotting were per-
formed as we previously described [25]. Several different primary
antibodies were used including: JMJD2B (Cell Signaling
Technology, Danvers, USA) and GAPDH (Santa Cruz Biotechnology,
Santa Cruz, USA). The secondary antibody incubations were
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visualized on the X-ray ﬁlm using an enhanced chemilumines-
cence ECL substrate. Three independent experiments were
performed.
2.5. Dual luciferase assay
HEK293 cells in a 96-well plate were transfected with 50nM
miR-491-5p or miR-NC. The cells were then co-transfected with
0.2 lg of vector with the wild-type or mutant 30UTR of JMJD2B
gene. After 48 h, luciferase activity was measured with the Dual-
Luciferase reporter assay system (Promega). Fireﬂy luciferase
activity was then normalized to the corresponding Renilla lucifer-
ase activity.
Luciferase assays were also performed to test estrogen respon-
siveness in the HEK293 cells transfected by an ERE-Luc reporter
construct. HEK293 cells were cotransfected with 1.0 lg of ERE-
Luc, 200 ng of pRL-TK, 200 ng of miR-491-5p and 0.2 lg of vector
with wild-type or mutant JMJD2B 30UTR. At 12–16 h posttransfec-
tion, the cells were induced with 10 nM E2 for 24 h before harvest-
ing for luciferase assays. Luciferase activity was measured and
reported as indicated above, and the values depicted were set rela-
tive to the hormone-depleted condition. All Luciferase assays were
performed in quadruplicate and repeated in three independent
experiments.
2.6. Chromatin immunoprecipitation assay
ChIP was performed using the SimpleChIP Kit (Cell Signaling
Technology, Inc.) according to the manufacturer’s instructions.
DNA/protein complexes were immunoprecipitated using antibod-
ies against H3K9me3 (ab8898, Abcam) and normal rabbit IgG anti-
bodies were used as negative controls. Immunoprecipitates were
eluted into 25 lL of TE buffer [10 mmol/L Tris–HCl (pH 8),
1 mmol/L EDTA]. One microliter of the DNA was used for a 10 lL
PCR reaction using the Absolute QPCR SYBR GreenMix (Thermo Sci-
entiﬁc) and a Roche LightCycler 480. Enrichments were calculated
as percentage of the input. For PCR ampliﬁcation of TFF1, GREB1
and TLE3 promoter regions, the following primer sequences were
utilized: TFF1, 50-CACCCCGTGAGCCACTGT-30 and 50-CTGCAGAAGT-
GATTCATAGTGAGAGAT-30; GREB1, 50-AGCAGTGAAAAAAAGTGTGG
CAACTGGG-30 and 50-CGACCCACAGAAAAGGCAGCAAACT-30; TLE3,
50-AATTGGGCTGCTTTGCAACC-30 and 50-GAGAGCAGTTCCAAATAG
GG-30. For PCR ampliﬁcation of upstream of TFF1 and GREB1
promoter regions, the following primer sequences were utilized:
TFF1, 50-AGATGGAAGGGTGCCTCTTT-30 and 50-TGTAGGAACCTGCA-
CACGAG-30; GREB1, 50-CCCATGAGAGAAAAGAGCCT-30 and 50-CCTA
AGCCAGCGCCTCAGT-30.
2.7. 5-aza-20-deoxycytidine treatments
Breast cancer cell lines were seeded into six-well plates
at a density of 1  105 per well and were cultured with
5-aza-20-deoxycytidine (5-AZA) (Sigma, St. Louis, MO, USA) at a
concentration of 2 lM in the growth medium. The 5-AZA-contain-
ing medium was exchanged every 24 h. After 72 h of treatment,
genomic DNA and total RNA was extracted for subsequent
experiments.
2.8. Methylation-speciﬁc PCR
Genomic DNA was extracted using the AllPrep DNA/RNA Kit
(Qiagen). One microgram total genomic DNAwas modiﬁed by sodi-
um bisulﬁte using the EZ DNA Methylation Kit (Zymed Research
Corp, Irvine, CA, USA). Methylation-speciﬁc PCR (MSP) was then
performed as described previously [26].2.9. Statistical analysis
SPSS 13.0 statistical software package (SPSS, Chicago, USA) was
used for statistical analysis and all values were presented as mean
with standard deviation (SD). A paired-samples T-test was used to
analyze differences in miR-491-5p expression between cervical
cancer and matched normal tissues. A chi-square test was used
to analyze differences in miR-491-5p promoter DNA methylation
status between cervical cancers and matched normal tissues. The
relationship between miR-491-5p and JMJD2B expression was
explored by Spearman’s correlation. For experiments in vitro, stu-
dent’s t-test was used to analyze the differences between two
groups. P < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. miR-491-5p expression is down-regulated in ERa-positive breast
cancers and cell lines
To further conﬁrm the altered expression of miR-491-5p in
breast cancer, we assessed the expression of miR-491-5p in 49 pri-
mary breast cancer tissues by quantitative real-time RT-PCR. We
found that the expression of miR-491-5p were much lower in the
ERa-positive breast cancer tissues than in ERa-negative ones
(Fig. 1A). Furthermore, we correlated miR-491-5p expression with
the presence of ERa in breast cancer tissues. The results showed
that miR-491-5p expression was inversely correlated with ERa
expression for breast cancer patients (r = 0.4877, P < 0.01)
(Fig. 1B). Meanwhile, we analyzedmiR-491-5p expression in differ-
ent breast cancer cell lines and found that miR-491-5p level was
signiﬁcantly lower in ERa-positive breast cancer cells compared
with ERa-negative ones (Fig. 1C). These data suggest that miR-
491-5p expression is closely associated with ERa expression levels
in ERa-positive breast cancer.
3.2. miR-491-5p inhibits estrogen-stimulated breast cancer cell
growth
Because miR-491-5p expression is signiﬁcantly lower in
ERa-positive breast cancer, we next examined whether
miR-491-5p is involved in tumor suppression in ERa-positive
breast cancer cells. Breast cancer cells with different ERa status
were transfected with miR-491-5p-mimics or negative controls
(Fig. 2A). Overexpression of miR-491-5p led to a notable reduction
of the cell proliferation and the colony formation of both MCF-7
and T47D cells in response to estrogen stimulation (Fig. 2B–D).
Moreover, overexpression of miR-491-5p did not signiﬁcantly
affect either cell proliferation or colony formation of ERa-negative
MDA-MB-231 and BT549 cell lines (Supplementary Fig. S1). To fur-
ther determine the mechanisms of miR-491-5p ovexpression on
breast cancer cell growth, we analyzed cell cycle and apoptosis
in transfected MCF-7 and T47D cells by ﬂow cytometry. miR-
491-5p-mimics resulted in a remarkable accumulation of cell cycle
at G1 phase as compared to that of the negative control (Fig. 2E).
There were no signiﬁcant changes in the apoptosis for both cell
lines (Supplementary Fig. S2). These results suggest that
miR-491-5p overexpression impaired the proliferative effects of
estrogen on ERa-positive breast cancer cells was, at least in part,
caused by cell cycle arrest.
3.3. Expression of JMJD2B is regulated by miR-491-5p in breast cancer
cells and inversely correlates with the miR-491-5p level in breast
cancer tissues
To elucidate the molecular mechanism through which
miR-491-5p affects breast cancer cells growth, we used a
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RNA.org, Microcosm Targets and EIMMo to search for the more
accurate potential targets of miR-491-5p. All of four approaches
predicted JMJD2B as a potential target for miR-491-5p, and the
30UTR of JMJD2B mRNA contains a highly conserved binding site
from position 1995 to 2001 for miR-491-5p seed sequence (the
core sequence that encompasses the ﬁrst 2–7 bases of the mature
miRNA, Fig. 3A). Because JMJD2B plays a critical oncogenic role in
ERa-positive breast cancer, JMJD2B was chosen for further study.
To validate whether JMJD2B was the target of miR-491-5p, we per-Fig. 1. miR-491-5p expression is down-regulated in ERa-positive human breast
cancer. (A) quantitative RT-PCR analysis shows that the expression levels of miR-
491-5p are much lower in the ERa-positive breast cancer tissues than in the ERa-
negative ones (ERa+, n = 26; ERa, n = 23; P < 0.01). Each sample was analyzed in
triplicate and normalized to U6. The relative expression was calculated using the
equation RQ = 244CT. (B) Correlation analysis shows an inverse correlation
between miR-491-5p and ERa mRNA expression in breast cancer tissues (n = 49,
P < 0.01). (C) miR-491-5p expression levels are lower in ER-positive breast cancer
cell lines. Expression level of miR-491-5p was detected by qRT-PCR in ER-positive
and ER-negative breast cancer cell lines. The relative expression of miR491-5p was
normalized to the endogenous control U6. Each sample was analyzed in triplicate.
The data represent the mean values of three independent experiments.⁄P < 0.05,
⁄⁄P < 0.01 compared with control group.formed Western blot analysis. The ectopic expression of miR-491-
5p signiﬁcantly inhibited the JMJD2B expression in MCF-7 and
T47D cells (Fig. 3B). We further investigated the correlation
between miR-491-5p and JMJD2B expression in breast cancer sam-
ples. qRT-PCR assays were performed on 26 pairs of ERa-positive
breast cancer and adjacent normal tissues to assess the expression
of miR-491-5p and JMJD2B. We found that JMJD2B expression was
signiﬁcantly inversely correlated with miR-491-5p expression both
in ERa-positive breast cancer tissues and in corresponding normal
tissues (Fig. 3C and Supplementary Fig. S3).
3.4. JMJD2B is a direct target of miR-491-5p
To further validate that JMJD2B is the direct target of miR-491-
5p, we constructed luciferase reporter vectors containing the tar-
get sequences of wild type JMJD2B 30UTR (WT) or the mutant
sequence (mutation of the putative miR-491-5p target site,
MUT). By cotransfection with miR-491-5p, Our results showed that
the miR-491-5p signiﬁcantly decreased the ﬁreﬂy luciferase activ-
ity in the reporter with wild type 30UTR, but the activity of mutant
30UTR vector remained unaffected. These results indicated that
miR-491-5p directly targets the JMJD2B through its 30UTR region
(Fig. 3D).
3.5. MiR-491-5p-mediated inhibition of JMJD2B is involved in the
suppression of estrogen-stimulated breast cancer cell growth
To explore the effect of miR-491-5p-mediated JMJD2B inhibi-
tion on estrogen-stimulated cell growth, we examined the biologic
functions of miR-491-5p mimics-transfected breast cancer cells by
up-regulated JMJD2B expression. A western blot analysis showed
that cotransfection of miR-491-5p-mimics and JMJD2B cDNA plas-
mid without its 30UTR signiﬁcantly rescued the down-regulation of
JMJD2B induced by miR-491-5p-mimics in MCF-7 and T47D cells
(Fig. 4A). We further found that restoration of JMJD2B expression
signiﬁcantly impaired the effect of miR-491-5p-mimics on breast
cancer cell proliferation and cell cycle progression in response to
estrogen stimulation (Fig. 4B–D). These results suggest that the
inhibition of estrogen stimulated breast cancer cell proliferation
and the induction of cell cycle arrest by miR-491-5p were mediat-
ed through down-regulation of JMJD2B.
3.6. MiR-491-5p modulates estrogen signaling
Because JMJD2B is a cofactor of estrogen receptor and enhances
the transcriptional activity of ER, we investigated whether miR-
491-5p has any effect on estrogen signaling. Cotransfection of
ERE-Luc with miR-491-5p-mimics and ERa expression plasmid in
HEK293 cells signiﬁcantly reduced the expression of the luciferase
reporter in the presence of estrogen (Fig. 5A). To further examine
the negative effect of miR-491-5p on estrogen signaling via
JMJD2B, we fused wild-type or mutated JMJD2B-30UTR to JMJD2B
expression plasmid, pcDNA-JMJD2B, by replacing the original
30UTR sequences of pcDNA3 plasmid. These constructs were tran-
siently transfected into HEK293 cells, along with ERE-Luc and
ERa expression plasmid. The results showed that transfection of
JMJD2B expression vector with wild type 30UTR did not rescue
the luciferase activity inhibited by miR-491-5p mimics. In contrast,
transfection of JMJD2B expression vector with mutant 30UTR
resulted in a signiﬁcant restoration of luciferase activity inhibited
by miR-491-5p-mimcs (Fig. 5B). To determine whether this
observed decrease in ER transcriptional activity translated to gene
expression, we next examined the mRNA expression of ERa-
regulated genes. Cells overexpressing miR-491-5p or negative con-
trol were cultured in presence of estrogen and mRNA expression
was assessed by qRT-PCR. Corresponding with the decrease in
Fig. 2. miR-491-5p inhibits ERa-positive breast cancer cell growth. (A) The expression level of miR-491-5p in breast cancer cells was evaluated by qRT-PCR after transfection
of miR-491-5p-mimics or negative controls. (B) MCF-7 and T47D cells were transfected with miR-491-5p-mimics or negative controls with or without 10 nmol/L E2
treatment. The MTT assay was performed to determine the proliferation of these cells. (C) Cell growth curve was performed to investigate the proliferation of these cells. (D)
Colony formation assay of MCF-7 and T47D cells transfected with miR-491-5p-mimics or negative controls with or without 10 nmol/L E2 treatment. (E) Effect of miR-491-5p-
mimics on MCF7 and T47D cell cycles was monitored by ﬂow cytometry with or without 10 nmol/L E2 treatment. ⁄P < 0.05, ⁄⁄P < 0.01 compared with control group.
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genes TFF1 and GREB1 were down-regulated in miR-491-5p over-
expressing cells relative to negative controls upon estrogen
stimulation (Fig. 5C), while overexpression of miR-491-5p did
not affect mRNA levels of the non-ERa-regulated gene TLE3 in
ERa-positive cells upon estrogen stimulation (Supplementary
Fig. S4A). Because JMJD2B can erase the H3K9me3 mark in ERa-ac-
tivated transcription, the level of H3K9me3 on the promoters of
TFF1, GREB1 and TLE3 gene as well as on the upstream region of
TFF1 and GREB1 promoter was examined in MCF-7 cells overex-pressing miR-491-5p in the presence of estrogen by quantitative
ChIP. As shown in Fig. 5D, overexpression of miR-491-5p resulted
in an increase level of H3K9me3 on the promoter of TFF1 and
GREB1 genes, whereas overexpression of miR-491-5p did not affect
the level of H3K9me3 either on the promoter of TLE3 gene or on
the upstream region of TFF1 and GREB1 promoter (Supplementary
Fig. S4B–D). These results clearly demonstrate that miR-491-5p
can effectively block ERa-mediated signaling by reduction of
JMJD2B expression and a substantial retention of H3K9me3 on
the promoter of the ERa-activated genes.
Fig. 3. JMJD2B is a direct target of miR-491-5p in breast cancer. (A) putative miR-491-5p binding site in 30UTR region of JMJD2B and interspecies conservation of seed
matching sequences (gray box). Mutation was generated in the JMJD2B 30UTR by mutating seed matching sequence. Either wild or mutant JMJD2B 30UTR was subcloned into
the dual-luciferase reporter plasmid. (B) Expression levels of JMJD2B were tested after miR-491-5p-mimics transfected into MCF-7 and T47D cells by western blot. (C) Inverse
correlation between miR-491-5p and JMJD2B in ERa-positive breast cancer tissues determined by spearman’s correlation analysis. (D) Luciferase reporter assays in MCF-7
and T47D cells. Cotransfection of wt or mut 30UTR with miRNAs as indicated.
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breast cancer
We further explored the mechanisms down-regulating
miR-491-5p expression in breast cancer. A previous study showed
that miR-491-5p expression could be regulated by DNA methyla-
tion in hepatocellular cancer [26]. Therefore, we investigated
whether miR-491-5p is also epigenetically suppressed in ERa-
positive breast cancer. We ﬁrst treated breast cancer cells with
different ERa status with 5-AZA. Compared with the controls,
miR-491-5p expression was signiﬁcantly increased in MCF-7
and T47D cells but was not altered in MDA-MB-231 and BT549
cells (Fig. 6A and Supplementary Fig. S5A). Moreover, treatment
of MCF-7 and T47D cells with 5-AZA remarkably reduced the
methylation status in the CpG islands of the miR-491-5p pro-
moter region as demonstrated by MS-PCR (Fig. 6B). We next ana-
lyzed the DNA methylation status of miR-491-5p promoter in
paired breast cancer and adjacent non-cancerous tissues. Data
indicated that miR-491-5p promoter was methylated in 84.62%
of ER-a positive breast cancer tissues and 34.62% of correspond-
ing control tissues (n = 26, Fig. 6C), while it was methylated in
30.43% of ER-a negative breast cancer tissues and 26.09% of cor-
responding control tissues (n = 23, Supplementary Fig. S5B). These
results indicated that DNA methylation may be involved in down-
regulation of miR-491-5p in ERa-positive breast cancer cells and
tissues.4. Discussion
Emerging evidence has shown that miRNAs are dysregulated in
various cancers and are deﬁned as tumor suppressors or oncogenes
[13]. Moreover, several studies have conﬁrmed a crucial role for
miRNAs in the progression and therapy of breast cancer [27,28].
MiR-491-5p has been reported to be involved in various cancers,
which is downregulated and functions as a potential tumor sup-
pressor in oral squamous cell carcinoma, hepatocellular carcinoma,
pancreatic cancer and ovarian carcinoma [20–23]. A previous miR-
NAs microarray based analysis has shown that the expression of
miR-491-5p in ERa-positive breast cancer tissues was much lower
than those in ERa-negative ones [20]. However, there are no lit-
erature reports investigating the expression, function, and
mechanisms of miR-491-5p in breast cancer. In the present study,
we further conﬁrmed that miR-491-5p was signiﬁcantly down-
regulated in ERa-positive breast cancer tissues and cell lines com-
pared with ERa-negative ones as indicated by qRT-PCR analysis.
Previous study has revealed that the dysregulation of miRNAs in
ER-positive breast cancer may indicate that these miRNAs have cri-
tical roles in ER signaling regulation [29]. Our results showed that
the treatment of ERa-positive breast cancer cells with miR-491-
5p-mimics substantially impaired their ability to proliferate in
response to estrogen by induction of cell cycle arrest at G1 phase,
which was consistent with the result reported by Leivonen et al.
that miR-491-5p could signiﬁcantly inhibited breast cancer cell
Fig. 4. Restoration of JMJD2B abrogates the antitumor effects of miR-491-5p-mimics in breast cancer cells. MCF-7 and T47D cells treated with 10 nmol/L E2 were
cotransfected with miR-491-5p-mimics and JMJD2B expression plasmid or negative controls. (A) Ectopic expression of JMJD2B reversed downregulation of JMJD2B induced
by miR-491-5p-mimics. (B and C) JMJD2B restoration impaired miR-491-5p mimics-induced cell proliferation suppression. (D) Ectopic expression of JMJD2B reversed miR-
491-5p-mimics induced cell cycle arrest.
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in this study [30]. These data indicated that downregulation of
miR-491-5p may be important for breast cancer cell growth and
miR-491-5p may act as a tumor suppressor in ERa-positive breast
cancer cells by inhibiting the estrogen signaling. Our ﬁndings along
with previous studies suggest that miR-491-5p may act as a com-
mon tumor suppressor. Unfortunately, we did not have enough
cases to investigate the relationship between deregulation of
miR-491-5p expression and clinical outcomes. Our future studies
will aim to elucidate this issue.
To further explore the molecular mechanism by which
miR-491-5p suppresses growth of breast cancer, we used four
bioinformatics algorithms to predict gene targets for miR-491-5p.JMJD2B was one of cancer-related genes predicted by all of these
algorithms, which was selected as a candidate target of miR-491-
5p for further research for the following reasons. JMJD2B, a histone
demethylase, is highly expressed in ERa-positive breast cancer and
plays important roles in the cellular function of ERa [8,10,31]. The
western blot results showed that the upregulation of miR-491-5p
inhibited the expression of JMJD2B in ERa-positive breast cancer
cells. Moreover, the inverse correlation between miR-491-5p and
JMJD2B expression in ERa-positive breast cancer tissues was fur-
ther conﬁrmed that miR-491-5p down-regulation resulted in
JMJD2B overexpression. Our luciferase activity data further
showed that miR-491-5p was able to directly target the 30UTR of
JMJD2B. We further showed that overexpression of JMJD2B
Fig. 5. miR-491-5p inhibits ERa-mediated signaling. (A) Luciferase activity in HEK293 cells transiently cotransfected with ERa expression plasmid, ERE-Luc reporter plasmid,
and miR-491-5p mimics in the absence or presence of 10 nmol/L E2. (B) Luciferase activity in HEK293 cells transiently cotransfected with JMJD2B expression plasmid
containing wild-type or mutant JMJD2B 30UTR, ERa expression plasmid, ERE-luc reporter plasmid and miR-491-5p mimics in the presence of 10 nmol/L E2. (C) The expression
level of ERa target genes, TFF1 and GREB1, were evaluated by qRT-PCR after transfection of miR-491-5p-mimics or negative controls into MCF-7 cells with or without
10 nmol/L E2 treatment. (D) the level of H3K9me3 on ERa target genes, TFF1 and GREB1, promoter were evaluated by qChIP assay after transfection of miR-491-5p-mimics or
negative controls into MCF-7 cells with or without 10 nmol/L E2 treatment.
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5p. These results suggest that miR-491-5p inhibits estrogen-in-
duced ERa-positive breast cancer cell proliferation by inducing
G1 arrest via reducing JMJD2B level, which are consistent with
the idea that estrogen affects mammary epithelial cells mainly
by promoting G1-to-S transition of the cell cycle [32]. In addition,
consistent with a previous study that JMJD2B acts as a co-regulator
in ERa signaling cascade and is required for the full induction of
ERa target genes through the demethylation of H3K9me3 in
ER-binding regions [31], we found that miR-491-5p was able to
signiﬁcantly impair the activity of an ERE-luciferase reporter and
restoration of miR-491-5p recognition-defective JMJD2B in these
cells was able to rescue estrogen-induced ERE-luciferase activity,
and that upregulation of miR-491-5p severely inhibited estrogen-
stimulated expression of endogenous ERa target genes, TFF1 and
GREB1, and resulted in an increased level of H3K9me3 on the pro-
moter of these genes. Several miRNAs are involved in regulating ER
signaling via targeting the ERa directly [16–18]. Although miRNAs
should be expected to inﬂuence estrogen signaling pathway by
altering coactivator levels, there are only few reports on coactiva-
tor regulation by miRNA directly affecting ER activity [33,34]. Thus,
our ﬁndings provided strong evidence that miRNAs might regulate
estrogen signaling through an alternative mechanism. Since
tamoxifen resistance remains as a major challenge for breastcancer therapy, our ﬁndings also have an important clinical
implication. Some studies have revealed that tamoxifen resistance
may be due to tamoxifen acquiring agonistic properties to transac-
tivate ERa [35] or ERa functioning in the absence of bound estro-
gen [36] and so on. Therefore, it is a potential strategy to
abrogate tamoxifen resistance by targeting ERa signaling pathway
downstream of interaction between estrogen and ERa. Cui et al.
reported that miR-873 can reverse tamoxifen resistance in breast
cancer cells by targeting CDK3 which can phosphorylate ERa and
enhance ER activity [37]. Thus miR-491-5p which regulates ER
activity by targeting ERa coactivator may also be able to reverse
tamoxifen resistance. This hypothesis awaits further studies.
MiRNAs have been described to be dysregulated by numerous
factors, including transcriptional regulation and chromosome
modiﬁcation. Previous studies have indicated that aberrant methy-
lation of promoter CpG islands led to the dysregulation of miRNAs
in ERa-positive breast cancer and these dysregulated miRNAs
could further affect the estrogen signaling [38,39]. Thus, we
hypothesized that miR-491-5p downregulation in ERa-positive
breast cancer may be at least partly mediated by DNA hypermethy-
lation. The hypothesis was veriﬁed as we showed that the CpG
island of miR-491-5p promoter was highly methylated in breast
cancer cells, but that the treatment with 5-AZA led to increase
the expression of miR-419-5p and demethylate miR-419-5p
Fig. 6. miR-491-5p is down-regulated by promoter DNA methylation in ERa-
positive breast cancer. (A) quantitative RT-PCR analyzed the expression levels of
miR-491-5p in MCF-7 and T47D cells following 2 lM 5-AZA treatment (72 h). (B)
Methylation-speciﬁc PCR of miR-491-5p promoter CpG islands in MCF-7 and T47D
cells after 2 lM 5-AZA treatment (M, methylation; U, unmethylation). (C) The
frequency of methylation-positive samples by MS-PCR was signiﬁcantly higher in
breast cancer group than that of corresponding control group (P < 0.01, Pearson Chi-
Square analysis). The y-axis shows the percentage of samples positive or negative
for methylation within each group.
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miR-419-5p methylation levels were higher in ERa-positive tumor
tissues than in adjacent normal tissues. This result is consistent
with a previous study showing that the expression of miR-491-
5p could be upregulated through DNA-demethylation in hepato-
cellular cancer cells [26]. Collectively, the results suggested that
methylation was an important mechanism for miR-491-5p down-
regulation in ERa-positive breast cancer.
Taken together, we have shown that miR-491-5p expression is
markedly downregulated in ERa-positive breast cancer tissues
and cells via its promoter DNA hypermethylation, and that overex-
pression miR-491-5p inhibits estrogen-stimulated breast cancer
cells growth by induction of cell cycle G1 arrest through directly
targeting JMJD2B. These ﬁndings suggest that upregulation of
miR-491-5p in ERa-positive breast cancers may be a promising
strategy for clinical therapies.
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